SCHEMBL520073

SCHEMBL520073

CNC(=O)c1cccc(N)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 2/20 0.63
HDAC6 Q9UBN7 2/20 0.63
ALDH1A1 P00352 2/20 0.58
KDM4E B2RXH2 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
HSD17B10 Q99714 1/20 0.56
PBRM1 Q86U86 1/20 0.55
KDM4C Q9H3R0 1/20 0.54
HDAC1 Q13547 2/20 0.53
HDAC3 O15379 1/20 0.53
BRAF P15056 1/20 0.53
HDAC4 P56524 1/20 0.53
HDAC7 Q8WUI4 1/20 0.53
HDAC2 Q92769 1/20 0.53
HDAC10 Q969S8 1/20 0.53
HDAC11 Q96DB2 1/20 0.53
HDAC9 Q9UKV0 1/20 0.53
HDAC5 Q9UQL6 1/20 0.53
NPC1 O15118 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29944867 1.00 HDAC8 (0.63) HDAC8HDAC6ALDH1A1KDM4ESMN1; SMN2
SCHEMBL5909363 0.85 HDAC8 (0.83) HDAC8HDAC6ALDH1A1KDM4ESMN1; SMN2
SCHEMBL8543766 0.85 ALDH1A1 (0.55) HDAC8HDAC6ALDH1A1KDM4ESMN1; SMN2
SCHEMBL9921285 0.83 SMN1; SMN2 (0.59) ALDH1A1KDM4ESMN1; SMN2NPSR1HSD17B10
SCHEMBL28308086 0.83 SMN1; SMN2 (0.58) HDAC8HDAC6ALDH1A1SMN1; SMN2PBRM1
SCHEMBL7188655 0.82 SMN1; SMN2 (0.54) HDAC8HDAC6ALDH1A1KDM4ESMN1; SMN2
SCHEMBL6999270 0.82 PBRM1 (0.58) ALDH1A1KDM4ESMN1; SMN2NPSR1HSD17B10
SCHEMBL6159659 0.82 KDM4E (0.62) HDAC8HDAC6ALDH1A1KDM4ESMN1; SMN2
SCHEMBL294944 0.82 KDM4E (0.66) ALDH1A1KDM4ESMN1; SMN2NPSR1HSD17B10
SCHEMBL31035124 0.82 KDM4E (0.66) ALDH1A1KDM4ESMN1; SMN2NPSR1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 661 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119194842-A Method for preparing uniform and compact carbon coating on surface of carbon fiber 山东理工大学 2024-12-27 CN claimed
CN-111100225-B Propylene polymerization method and device 中国石油化工股份有限公司 2022-08-19 CN claimed
CN-114395129-A Preparation method of polyether polyol with photodegradation characteristic 山东一诺威新材料有限公司 2022-04-26 CN claimed
CN-109337282-B High-thermal-stability polyformaldehyde resin and preparation method thereof 万华化学集团股份有限公司 2021-03-09 CN claimed
CN-112127179-A Low-temperature forebath scouring and dyeing enzyme treatment auxiliary agent 清远瑞华助剂有限公司 2020-12-25 CN claimed
CN-108963389-B Gelable system for lithium-air battery and preparation method and application thereof 北京师范大学 2020-11-13 CN claimed
CN-111100225-A Propylene polymerization method and device 中国石油化工股份有限公司 2020-05-05 CN claimed
EP-3637525-A1 FLEXIBLE ALL-SOLID-STATE LITHIUM-ION SECONDARY BATTERY AND MANUFACTURING METHOD THEREFOR Beijing Normal University (CN) 2020-04-15 EP claimed
EP-3637524-A1 GELATINIZED SYSTEM AND APPLICATIONS IN LITHIUM AIR BATTERY, SUPER CAPACITOR OR CAPACITOR BATTERY IN ORGANIC SYSTEM Beijing Normal University (CN) 2020-04-15 EP claimed
US-20200099097-A1 GELABLE SYSTEM AND USES THEREOF IN LITHIUM-AIR BATTERIES, ORGANIC SUPERCAPACITORS OR CAPACITOR BATTERIES BEIJING NORMAL UNIVERSITY (CN) 2020-03-26 US claimed
EP-1917246-B1 BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS NOVARTIS AG (CH) 2009-11-11 EP claimed
WO-2008122787-A1 PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE EVOTEC AG (DE) 2008-10-16 WO claimed
US-20080227782-A1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2008-09-18 US claimed
EP-1937652-A1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS Aventis Pharmaceuticals Inc. (US) 2008-07-02 EP claimed
EP-1917246-A1 BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS Novartis AG (CH) 2008-05-07 EP claimed
CN-100339442-C Method for preparing organic pigment of red benzimidazolones UNIV HUADONG TECHNOLOGY (CN) 2007-09-26 CN claimed
WO-2007041634-A1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2007-04-12 WO claimed
WO-2007020046-A1 BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS NOVARTIS AG (CH) 2007-02-22 WO claimed
CN-1569968-A Yellow, orange benzimidazolone like azo dye making method UNIV EAST CHINA SCIENCE & TECH (CN) 2005-01-26 CN claimed
CN-1563202-A Method for preparing organic pigment of red benzimidazolones UNIV HUADONG TECHNOLOGY (CN) 2005-01-12 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227782-A1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS HRH2, HRH1, LTC4S HDAC8 2170/4885HDAC6 1580/4885ALDH1A1 871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.